X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Cipla with Aventis Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

CIPLA vs SANOFI INDIA - Comparison Results

CIPLA    Change

Cipla is one of the largest pharma companies in the domestic market and has presence in formulations and bulk drugs manufacturing. All the bulk drug manufacturing facilities of the company have been approved by various authorities including the US FD... More

SANOFI INDIA 
   Change

Sanofi India (the erstwhile Aventis Pharma), the 60% subsidiary of Sanofi-Aventis SA, France, is one of the largest pharma MNCs in India with a turnover of over Rs 13.2 bn in CY11. Domestic sales constituted 81% of total sales in CY11 and exports con... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    CIPLA SANOFI INDIA CIPLA/
SANOFI INDIA
 
P/E (TTM) x 40.1 39.2 102.2% View Chart
P/BV x 3.7 8.5 43.6% View Chart
Dividend Yield % 0.5 1.1 43.1%  

Financials

 CIPLA   SANOFI INDIA
EQUITY SHARE DATA
    CIPLA
Mar-18
SANOFI INDIA
Dec-16
CIPLA/
SANOFI INDIA
5-Yr Chart
Click to enlarge
High Rs6634,560 14.5%   
Low Rs4794,400 10.9%   
Sales per share (Unadj.) Rs189.01,028.5 18.4%  
Earnings per share (Unadj.) Rs17.6129.0 13.6%  
Cash flow per share (Unadj.) Rs34.0186.0 18.3%  
Dividends per share (Unadj.) Rs3.0068.00 4.4%  
Dividend yield (eoy) %0.51.5 34.6%  
Book value per share (Unadj.) Rs176.7753.6 23.5%  
Shares outstanding (eoy) m805.1223.03 3,496.0%   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x3.04.4 69.3%   
Avg P/E ratio x32.534.7 93.4%  
P/CF ratio (eoy) x16.824.1 69.7%  
Price / Book Value ratio x3.25.9 54.3%  
Dividend payout %17.152.7 32.3%   
Avg Mkt Cap Rs m459,724103,174 445.6%   
No. of employees `00023.63.6 651.7%   
Total wages/salary Rs m26,9013,592 748.9%   
Avg. sales/employee Rs Th6,446.16,537.7 98.6%   
Avg. wages/employee Rs Th1,139.4991.4 114.9%   
Avg. net profit/employee Rs Th600.0819.8 73.2%   
INCOME DATA
Net Sales Rs m152,19323,686 642.5%  
Other income Rs m3,577708 505.2%   
Total revenues Rs m155,76924,394 638.6%   
Gross profit Rs m28,2645,281 535.2%  
Depreciation Rs m13,2281,313 1,007.5%   
Interest Rs m1,14215 7,615.3%   
Profit before tax Rs m17,4704,661 374.8%   
Minority Interest Rs m00-   
Prior Period Items Rs m-280-   
Extraordinary Inc (Exp) Rs m-7750-   
Tax Rs m2,5011,691 147.9%   
Profit after tax Rs m14,1662,970 477.0%  
Gross profit margin %18.622.3 83.3%  
Effective tax rate %14.336.3 39.5%   
Net profit margin %9.312.5 74.2%  
BALANCE SHEET DATA
Current assets Rs m108,14115,673 690.0%   
Current liabilities Rs m38,3226,678 573.9%   
Net working cap to sales %45.938.0 120.8%  
Current ratio x2.82.3 120.2%  
Inventory Days Days9776 127.7%  
Debtors Days Days7422 333.5%  
Net fixed assets Rs m109,4118,098 1,351.1%   
Share capital Rs m1,610230 699.2%   
"Free" reserves Rs m140,68217,088 823.3%   
Net worth Rs m142,29217,356 819.8%   
Long term debt Rs m36,6210-   
Total assets Rs m228,60625,400 900.0%  
Interest coverage x16.3311.7 5.2%   
Debt to equity ratio x0.30-  
Sales to assets ratio x0.70.9 71.4%   
Return on assets %6.711.8 57.0%  
Return on equity %10.017.1 58.2%  
Return on capital %10.026.9 36.9%  
Exports to sales %32.824.5 133.8%   
Imports to sales %028.0 0.0%   
Exports (fob) Rs m49,8835,801 859.9%   
Imports (cif) Rs mNA6,627 0.0%   
Fx inflow Rs m51,6917,145 723.5%   
Fx outflow Rs m21,0336,846 307.2%   
Net fx Rs m30,658299 10,253.4%   
CASH FLOW
From Operations Rs m14,6283,226 453.4%  
From Investments Rs m-8,540-1,555 549.2%  
From Financial Activity Rs m-3,855-1,818 212.0%  
Net Cashflow Rs m2,431-147 -1,653.8%  

Share Holding

Indian Promoters % 16.0 0.0 -  
Foreign collaborators % 20.8 60.4 34.4%  
Indian inst/Mut Fund % 12.2 14.4 84.7%  
FIIs % 23.7 14.6 162.3%  
ADR/GDR % 1.1 0.0 -  
Free float % 26.2 10.5 249.5%  
Shareholders   161,166 15,184 1,061.4%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare CIPLA With:   ASTRAZENECA PHARMA  DR. DATSONS LABS  ELDER PHARMA  GSK PHARMA  PANACEA BIOTECH  

Compare CIPLA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Opens 220 Points Higher; Metal & Realty Stocks Gain the Most(09:30 am)

Asian stock markets are higher today as Japanese and Hong Kong shares show gains. The Nikkei 225 is up 0.5% while the Hang Seng is up 0.5%.

Related Views on News

CIPLA Announces Quarterly Results (1QFY19); Net Profit Up 4.7% (Quarterly Result Update)

Aug 10, 2018 | Updated on Aug 10, 2018

For the quarter ended June 2018, CIPLA has posted a net profit of Rs 4 bn (up 4.7% YoY). Sales on the other hand came in at Rs 39 bn (up 11.7% YoY). Read on for a complete analysis of CIPLA's quarterly results.

SANOFI INDIA Announces Quarterly Results (1QFY19); Net Profit Up 35.1% (Quarterly Result Update)

Jul 27, 2018 | Updated on Jul 27, 2018

For the quarter ended June 2018, SANOFI INDIA has posted a net profit of Rs 996 m (up 35.1% YoY). Sales on the other hand came in at Rs 7 bn (up 13.8% YoY). Read on for a complete analysis of SANOFI INDIA's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

This is a Must-Have Stock for Your Portfolio(The 5 Minute Wrapup)

Aug 8, 2018

Tanushree just released the permanent wealth blueprint report. This report includes three safe and steady stocks. I like one in particular. Here's why

Trading in These Times: 8% Gains in 3 Days!(Profit Hunter)

Aug 9, 2018

Here are 2 stocks you can buy right now! And there are plenty more opportunities to come...

Banks are Raising FD Rates and That's Good News(Vivek Kaul's Diary)

Aug 7, 2018

Lending to the retail segment remains strong, whereas lending to the service sector has picked up dramatically.

Why HDFC Equity Fund Disappointed Its Investors(Outside View)

Aug 9, 2018

Though popular, HDFC Equity Fund is not among the best performers anymore. Here is the reason behind its underperformance that has left investors disappointed.

HDFC AMC Makes 65% Listing Gains! Should It Attract Mutual Fund Investors?(Outside View)

Aug 8, 2018

PersonalFN explains if investors should invest in schemes of HDFC Mutual Fund looking at the listing gains of HDFC AMC.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

CIPLA SHARE PRICE


Aug 17, 2018 11:29 AM

TRACK CIPLA

COMPARE CIPLA WITH

MARKET STATS